Related Experiment Video

Updated: Jun 16, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Ras-induced resistance to lapatinib is overcome by MEK inhibition

Gabriele Zoppoli1, Eva Moran, Debora Soncini

  • 1Department of Internal Medicine, University of Genoa, 16132 Genoa, Italy.

Current Cancer Drug Targets
|January 22, 2010
PubMed

Insights

Ras signaling pathways can cause resistance to lapatinib in HER2+ breast cancer. MEK inhibitors combined with lapatinib may overcome this resistance, improving treatment efficacy for these tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Lapatinib is a dual tyrosine kinase inhibitor effective against HER2+ breast cancer but faces resistance.
  • Ras signaling, often elevated through H-ras overexpression or Brk amplification, contributes to therapeutic resistance.
  • Understanding resistance mechanisms is crucial for optimizing HER2-targeted therapies.

Purpose of the Study:

  • To investigate the role of ras signaling in lapatinib resistance in HER2+ breast cancer.
  • To explore whether MEK inhibition can overcome ras-mediated lapatinib resistance.

Main Methods:

  • Utilized SKBR3 and BT474 HER2+ breast cancer cell lines.
  • Overexpressed H-ras or an oncogenic ras allele (ras V12) to model resistance.
  • Administered lapatinib alone or in combination with MEK inhibitor U0126.

Main Results:

  • Ras overexpression or oncogenic ras V12 expression reduced lapatinib sensitivity, mimicking PI3KCA/Akt pathway activation.
  • MEK inhibition with U0126 successfully overcame lapatinib resistance induced by ras.
  • The MEK-Erk pathway was identified as critical in ras-induced lapatinib resistance.

Conclusions:

  • Overexpressed or mutated ras acts as a significant modifier of lapatinib response in HER2+ breast cancer.
  • Combining MEK inhibitors with lapatinib presents a potential strategy to circumvent ras-mediated resistance.
  • This combination therapy could enhance lapatinib's efficacy in tumors with elevated ras signaling.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...